KLK3 and prostate cancer: The results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) showed that PCa mortality rates can be decreased by PSA testing (9–12), whereas earlier results from the Prostate, Lung, Colorectal and Ovarian (PLCO) trial showed that screening was not associated with reduced PCa mortality rates (13–15).